Sign in
ALVO Stock Price, Chart, Stats & News
Alvotech
Save
1.32B
Market cap
–
Current P/E
7.91x
Forward P/E
ALVO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 55.42% |
Operating margin | 7.61% |
Pretax margin | 9.15% |
Net margin | 12.17% |
Effective tax rate | -33.05% |
ROA | 4.93% |
ROE | -26.11% |
D/E | -7.25x |
Interest coverage ratio | -0.86x |
ALVO valuation
P/E | – |
P/S | 1.70x |
P/B | -5.28x |
P/CF | -35.26x |
P/FCF | -8.54x |
P/OCF | -35.26x |
PEG | 1.61x |
EV multiple | -3.72x |
About
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
Similar securities
Based on sector and market capitalization
Report issue